Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

SPARTACUS Trial (Sotagliflozin as Prevention of Antracycline-Related Toxicity in Adipose, Cardiac and mUskuloSkeletal Tissues)

This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.

Inclusion Criteria

• Patients ≥ 18 years
• Newly diagnosed lymphoma
• Scheduled to receive high-dose anthracycline (cumulative dose ≥ 300 mg/m2)
• Eastern Cooperative Oncology Group (ECOG) performance status 0-3

Exclusion Criteria

• Prior anthracycline treatment
• Previous malignancy requiring any chemotherapy or radiotherapy
• Previous treatment with SGLT2i (eg due to T2DM) or SGLT1/2i
• Previous heart failure (HF patients should already be on SGLT2i as per guidelines)
• LVEF<40% (even in the absence of HF):
• Pregnancy or breastfeeding
• Standard contraindication to MRI (claustrophobia, non-MRI compatible devices)